The United Kingdom and the United States have secured a major bilateral deal that will preserve no duties on UK pharmaceutical products being sold in the US market.
Key Provisions of the Deal
As part of the deal, the UK has pledged to increase funding on medicines through the NHS. This pledge ensures that import taxes on these vital products will be held at zero for a duration of 36 months.
This development comes after recent threats to significantly raise import taxes on patented pharmaceutical imports, with increases discussed as high as 100%.
"This deal between the Britain bolsters the international landscape for new treatments and introduces long-overdue fairness to transatlantic drug exports," a release said.
Trade Impact
Drugs constitute one of the the United Kingdom's biggest goods shipped to the United States, which is by far the largest market for major British pharmaceutical firms.
Export figures show that in the 12 months leading up to last September, the UK sold medicines worth £11.1bn to the US. This amount represented a significant portion of British export trade in that period.
"This deal protects jobs, stimulates capital expenditure and paves the way for the UK to establish itself as a global hub for biotech and pharma," a minister stated.
Key NHS Changes
The pact includes several key pledges from the United Kingdom:
- Revised Affordability Limit: The UK will increase the cost ceiling at which it considers new treatments to be unaffordable by twenty-five percent.
- Increased NHS Spending: There is a target to raise overall public funding on treatments from 0.3% of GDP to 0.6% over the next decade.
- Refund Ceiling: The sum manufacturers must return to the NHS to stay within budget will be restricted at 15%. Last year, rebates exceeded 20%.
Industry Background
This agreement follows a ongoing dispute between the pharmaceutical industry and the British authorities over spending levels and regulatory access.
These tensions were heightened by arguments that US patients were charged several times more for the equivalent treatments than patients in the Britain and the EU.
In recent months, several large manufacturing plans in the UK have been delayed or scrapped, while major expansions have been announced toward American operations.
A senior figure acknowledged that the NHS needed to invest a greater share on treatments, noting that its expenditure on drugs had declined as a share of its total funding over the past decade.
